Research & Innovation
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Meet our Team
- Why Choose Us
-
Current Trials
- Back
- Current Trials
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric Cancer Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- About Oncology Trials
- Glossary of Terms
- Heart and Vascular
- Trauma and Critical Care
- Neurosciences
- Gastroenterology
- Orthopedics
- Gynecology
- Pulmonary Medicine
- Infectious Diseases
- Wound Care
- Internal Medicine
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- GME Data Outcomes
- Post Doctoral Research Fellowship
- Research Volunteer Program
- Institutional Review Board
- St. Luke's
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Meet our Team
- Why Choose Us
-
Current Trials
- Back
- Current Trials
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric Cancer Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- About Oncology Trials
- Glossary of Terms
- Heart and Vascular
- Trauma and Critical Care
- Neurosciences
- Gastroenterology
- Orthopedics
- Gynecology
- Pulmonary Medicine
- Infectious Diseases
- Wound Care
- Internal Medicine
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- GME Data Outcomes
- Post Doctoral Research Fellowship
- Research Volunteer Program
- Institutional Review Board
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Why Choose Us
-
Current Trials
- Back
- Current Trials
- Gastroenterology
- Heart and Vascular
- Infectious Diseases
- Internal Medicine
- Neurosciences
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric / Esophageal Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- St. Luke's
- About Oncology Trials
- Glossary of Terms
- St. Luke's
- Orthopedics
- Pediatrics
- Pulmonary Medicine
- Trauma and Critical Care
- Women’s Health
- Wound Care
- St. Luke's
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- St. Luke's
- GME Data & Outcomes
- Post Doctoral Research
- Research Volunteer Program
-
Institutional Review Board
- Back
- Institutional Review Board
- IRB Membership
- Resident and Fellow Data Request Form
- How do I submit to the IRB
- Policy on Case Reports
- Policy on Multicenter Retrospective Data Sharing
- Fee Schedule
- Policies & Procedures Manual
- Cayuse Tutorial
- Internal Academic Research Study Approval Signature Form
- Forms
- Request for Central IRB Form
- FAQs
- Contact Us
- St. Luke's
- St. Luke's
- 1-866-STLUKES
Clinical Trials
Lutonix AV PAS
A Prospective, Global, Multicenter, Single Arm Post-Approval Study Investigating the Clinical Use and Safety of the LutonixTM Drug Coated Balloon PTA Catheter for the Treatment of Dysfunctional AV Fistulae (Lutonix AV PAS).
Close
To demonstrate safety and assess the clinical use and outcomes of the LUTONIXTM DCB for treatment of dysfunctional AV fistulae located in the arm in a heterogeneous patient population in real world clinical practice.
Close
- Male or non-pregnant, non-breastfeeding female ≥18 years of age;
- Subject is willing to provide informed consent, and is willing to co ply with the protocol-required follow up visits;
- Target lesion must be a mature arteriovenous fistula located in the arm presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines;
- Subject has a target lesion that can be treated with available LUTONIXTM DCB according to the Instructions For Use (IFU);
- Venous stenosis of an AV fistula in which the target lesion is located from the anastomosis to the axillosubclavian junction, as defined by insertion of the cephalic vein;
- Successful pre-dilation of the target lesion with an uncoated percutaneous transluminal angioplasty (PTA) balloon defined as:
- a) No clinically significant dissection;
- b) No extravasation requiring treatment;
- c) Residual stenosis ≤30% by angiographic measurement;
- d) Ability to completely efface the waist using the pre-dilation balloon.
Close
INARI MEDICAL- PEERLESS_RCT
Close
FlowTriever System versus Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism (PE).
Close
Subjects must meet each of the following criteria to be included in the study:
1. Age ≥18 years old
2. Echo, computed tomographic pulmonary angiography (CTPA), or pulmonary angiographic evidence of any proximal filling defect in at least one main or lobar pulmonary artery
3. Including ALL of the following:
a. Clinical signs and symptoms consistent with acute PE, or PESI class III-V, or sPESI
AND
b. Hemodynamically stable
AND
c. RV dysfunction on echocardiography or CT
AND
d. Any one or more of the following present at the time of diagnosis:
i. Elevated cardiac troponin levels
ii. History of heart failure
iii. History of chronic lung disease
iv. Heart rate ≥ 110 beats per minute
v. SBP <100mmHg
vi. Respiratory rate ≥ 30 breaths per minute
vii. O2 saturation <90%
viii. Syncope related to PE
ix. Elevated lactate
4. Intervention planned to begin within 72 hours of the later of either
a. Confirmed PE diagnosis
OR
b. If transferring from another hospital, arrival at the treating hospital
5. Symptom onset within 14 days of confirmed PE diagnosis
Close
Research
Interested in a
Clinical Trial?